Here's Why TG Therapeutics Stock Is Getting Hammered Today
TG Therapeutics (NASDAQ: TGTX) is falling today in response to a disappointing Q2 earnings report. Investors, disappointed with lackluster sales of the company's new cancer drug, have beaten the biotech stock 21.5% lower as of 1:29 p.m. EDT on Monday.
On Monday morning, TG Therapeutics reported a Q2 loss of $78.5 million. This was significantly more than Wall Street analysts following the company were expecting. The net loss worked out to $0.59 per share, which was $0.11 less than consensus expectations.
Image source: Getty Images.
Source Fool.com
